Shamsuddin Khwaja, MD
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Fresno, CANPI 1679570527
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $108,150 of the $158,231 with a category attached, or 68.3%. Abiomed accounts for 80.6% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $45,408 and has fallen 96.7% since, to $1,512 in 2025. Among thoracic surgery (cardiothoracic vascular surgery) clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 370 payments — averaging $427.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$128K
- Atricure, Inc.$8K
- Medical Device Business Services, Inc.$6K
- Abbott$5K
- Artivion, Inc.$2K
- Edwards Lifesciences$2K
- plus $8K from 30 others
Across 23 payments — averaging $1268.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$29K
What the payments were for
- Consulting fees$13,4108%
- Speaking & faculty fees$108,15068%
- Travel & lodging$19,38912%
- Food & beverage$17,06811%
- Education$2140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 127 | $127,604 |
| Atricure, Inc. | 25 | $8,245 |
| Medical Device Business Services, Inc. | 1 | $5,850 |
| Abbott | 71 | $4,747 |
| Artivion, Inc. | 20 | $2,025 |
| Edwards Lifesciences | 22 | $1,926 |
| Johnson & Johnson(2 entities) | 15 | $1,893 |
| Medtronic(2 entities) | 15 | $1,053 |
| Bolton Medical Inc | 3 | $880 |
| Getinge USA Sales, LLC | 6 | $852 |
| Zimmer Biomet | 7 | $539 |
| AstraZeneca(2 entities) | 6 | $288 |
| LSI Solutions Inc | 3 | $244 |
| Boston Scientific | 1 | $233 |
| Hemosonics LLC | 2 | $230 |
| Baxter Healthcare | 4 | $192 |
| Octapharma USA, Inc. | 2 | $169 |
| Integra Lifesciences Corporation | 2 | $148 |
| Cvrx, Inc. | 3 | $146 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $140 |
| BD | 4 | $118 |
| Veran Medical Technologies, Inc. | 2 | $118 |
| Teleflex LLC | 1 | $91 |
| Werfen USA LLC | 1 | $91 |
| Kls-martin L.p. | 5 | $80 |
| Clearflow Inc. | 1 | $63 |
| Upsher-smith Laboratories LLC | 3 | $54 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Davol Inc. | 2 | $30 |
| Kestra Medical Technology Services, Inc. | 1 | $29 |
| Dilon Technologies, Inc. | 1 | $25 |
| Cornerstone Medical Associates, Inc. | 1 | $20 |
| Optinose US, Inc. | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $18 |
| Stryker | 1 | $17 |
| Conmed Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$124,922
- DERMABOND$7,410
- STRATAFIX$7,410
- SURGICEL NU-KNIT$7,410
- VISTASEAL$7,410
- ATRICURE SYNERGY ABLATION SYSTEM$6,937
- Epic$1,023
- TREO ABDOMINAL STENT-GRAFT SYSTEM$800
- Vasoview Hemopro 2$785
- Trifecta GT Tissue Heart Valve$673
- Tendyne Mitral Valve System$581
- INSPIRIS RESILIA aortic valve$479
- ON-X AORTIC HEART VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER$457
- KONECT RESILIA$295
- HeartMate 3 Left Ventricular Dev$285
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$274
- Penditure$271
- Avalus$259
- STERNALOCK BLU SYSTEM$234
- Watchman$233
How this compares
$158,231 in reported general payments places this provider in the 90th percentile of 546 thoracic surgery (cardiothoracic vascular surgery) providers in California.
See all thoracic surgery (cardiothoracic vascular surgery) providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 28 | $22,111 |
| Amiodarone Hcl | 26 | $530 |
| Metoprolol Tartrate | 90 | $457 |
| Furosemide | 58 | $246 |
| ClopidogrelClopidogrel Bisulfate | 31 | $223 |
| Atorvastatin Calcium | 25 | $201 |
| Amlodipine Besylate | 33 | $178 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $157 |
| Warfarin Sodium | 29 | $62 |
| Carvedilol | 17 | $24 |
Paid to pharmacies, not to this prescriber.
Other thoracic surgery (cardiothoracic vascular surgery) in Fresno
- Thomas FogartyPortola Valley$3.7M
- Steven GundryPalm Springs$1.6M
- Armin KiankhooySaint Helena$941K
- Ara KlijianMurrieta$916K
- Gregory FontanaThousand Oaks$875K
- Gansevoort DunningtonSaint Helena$764K
- Wilson TsaiWalnut Creek$680K
- Fernando FleischmanLos Angeles$608K
- Harmik SoukiasianLos Angeles$577K
- Ali KhoynezhadLong Beach$476K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.